Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

Dasatinib, a second-generation tyrosine kinase inhibitor, is used for treating patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who are resistant or intolerant to imatinib. The common adverse effects associated to its use include myelosuppression, nausea, diarrhea,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhe, Wang, Fei, Zhang, Xiaoping, Gao, Chong, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423504/
https://www.ncbi.nlm.nih.gov/pubmed/25960668
http://dx.doi.org/10.2147/OTT.S83961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423504/
https://www.ncbi.nlm.nih.gov/pubmed/25960668
http://dx.doi.org/10.2147/OTT.S83961

Ejemplares similares